British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010

HIV Medicine

Volumn 11, Issue 10, 2010, Pages 611-619

  Gilleece, Y ^a   Chadwick, D R ^a   Breuer, J ^a   Hawkins, D ^a   Smit, E ^a   McCrae, L X ^a   Pillay, D ^a   Smith, N ^a   Anderson, J ^a  

^a BHIVA Secretariat Mediscript Ltd   (United Kingdom)

Author keywords

Drug resistance; Dual HIV infection; Highly active antiretroviral therapy; HIV; HIV 2; Pregnancy; Treatment

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; ELVITEGRAVIR; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THYMIDINE DERIVATIVE; TIPRANAVIR; VIRUS CAPSID ANTIGEN; ZIDOVUDINE;

ARTICLE; BLOOD TRANSFUSION; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HETEROSEXUALITY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INJECTION; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; SALVAGE THERAPY; SEROCONVERSION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 77958593687     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00889.x     Document Type: Article

References (79)

1. Månsson F, Biague A, Da Silva ZJ et al. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS 2009; 23: 1575-1582.
2. Pfutzner A, Dietrich U, Von Eichel U et al. HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype. J Acquir Immune Defic Syndr 1992; 5: 972-977.
3. Cazein F, Hamers F, Alix J, Brunet JB. Prevalence of HIV-2 in Europe. Euro Surveill 1996; 1: 21-23.
4. CDC. Update: HIV-2 infection among blood and plasma donors-United States, June 1992-June 1995. Morb Mortal Wkly Rep 1995; 44: 603-606.
5. Health Protection Agency Centre for Infections, Health Protection Scotland and UCL Institute of Child Health. Unpublished HIV Diagnoses Surveillance Tables 01:2010. Available at (accessed 27 April 2010).
6. Horsburgh CR Jr, Holmberg SD. The global distribution of human immunodeficiency virus type 2 (HIV-2) infection. Transfusion 1988; 28: 192-195.
7. Kanki PJ, Travers KU, Mboup S et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343: 943-946.
8. Adjorlolo-Johnson G, De Cock KM, Ekpini E et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272: 462-466.
9. Morgan G, Wilkins HA, Pepin J et al. AIDS following mother-to-child transmission of HIV-2. AIDS 1990; 4: 879-882.
10. Matheron S, Courpotin C, Simon F et al. Vertical transmission of HIV-2. Lancet 1990; 335: 1103-1104.
11. Gueudin M, Damond F, Braun J et al. Differences in proviral DNA load between HIV-1- and HIV-2-infected patients. AIDS 2008; 22: 211-215.
12. Pepin J, Dunn D, Gaye I et al. HIV-2 infection among prostitutes working in The Gambia: association with serological evidence of genital ulcer diseases and with generalized lymphadenopathy. AIDS 1991; 5: 69-75.
13. Pepin J, Quigley M, Todd J et al. Association between HIV-2 infection and genital ulcer diseases among male sexually transmitted disease patients in The Gambia. AIDS 1992; 6: 489-493.
14. Miyazaki M. Epidemiological characteristics of human immunodeficiency virus type-2 infection in Africa. Int J STD AIDS 1995; 6: 75-80.
15. Harrison LH, Da Silva AP, Gayle HD et al. Risk factors for HIV-2 infection in Guinea-Bissau. J Acquir Immune Defic Syndr 1991; 4: 1155-1160.
16. Marlink R, Kanki P, Thior I et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265: 1587-1590.
17. Jaffar S, Wilkins A, Ngom PT et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 327-332.
18. Whittle H, Morris J, Todd J et al. HIV-2 infected patients survive longer than HIV-1 infected patients. AIDS 1994; 8: 1617-1620.
19. Schim van der Loeff M, Jaffar S, Aveika A et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in the Gambia. AIDS 2002; 16: 1775-1783.
20. Berry N, Jaffar S, Schim van der Loeff M et al. Low level viraemia and high CD4 % predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res and Human Retr 2002; 18: 1167-1173.
21. Matheron S, Mendoza-Sassi G, Simon F et al. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11: 934-936.
22. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81: 5325-5330.
23. Gilbert PB, McKeague IW, Eisen G et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22: 573-593.
24. Otten RA, Adams DR, Kim CN et al. Chronic HIV-2 infection protects against total CD4+ cell depletion and rapid disease progression induced by SHIV89.6p challenge. AIDS 2004; 18: 1127-1135.
25. Holmgren B, Da Silva Z, Larsen O et al. Dual infections with HIV-1, HIV-2 and HTLV-1 are more common in older women than in men in Guinea-Bissau. AIDS 2003; 17: 241-253.
26. Koblavi-Deme S, Kestens L, Hanson D et al. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Cote d'Ivoire. AIDS 2004; 18: 413-419.
27. Peeters M, Gershy-Damet GM, Fransen K et al. Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 1992; 340: 339-340.
28. Damond F, Loussert-Ajaka I, Apetrei C et al. Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA. J Clin Microbiol 1998; 36: 809-811.
29. Damond F, Benard A, Ruelle J et al. Quality control assessment of human virus type 2 immunodeficiency (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46: 2088-2091.
30. Andersson S, Norrgren H, Da Silva Z et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160: 3286-3293.
31. Matheron S, Pueyo S, Damond F et al. for the French HIV-2 Cohort Study Group. Factors associated with clinical progression in HIV-2-infected patients: the French ANRS cohort. AIDS 2003; 17: 2593-2601.
32. Ariyoshi K, Jaffar S, Alabi AS et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2 infected patients in West Africa. AIDS 2000; 14: 339-344.
33. Smith NA, Shaw T, Berry N et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 2001; 42: 126-133.
34. Drylewicz J, Matheron S, Lazaro E et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22: 457-468.
35. Adjé-Touré CA, Cheingsong R, Garcia-Lerma JG et al. Antiretroviral therapy in HIV-2 infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS 2003; 17 (Suppl. 3): S49-S54.
36. Van der Ende ME, Prins JM, Brinkman K et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2 infected patients. AIDS 2003; 17 (Suppl. 3): S55-S61.
37. Matheron S, Damond F, Benard A, Taieb A, Campa P. CD4 recovery in treated HIV-2 infected adults is lower than expected: results from the France ANRS CO5 HIV-2 cohort. AIDS 2006; 20: 459-462.
38. Damond F, Collin G, Descamps D et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005; 43: 4234-4236.
39. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stewart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35 - A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA 2002; 99: 14410-14415.
40. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9: 3-12.
41. Smith RA, Anderson DJ, Pyrak CL, Kiviat NB, Gottlieb GS, Preston BD. Low genetic barrier to nucleoside analogue resistance in HIV-2. Antivir Ther 2007; 12: S137.
42. Rodes B, Holguin A, Soriano V et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38: 1370-1374.
43. Van der Ende ME, Schutten M, Ly TD et al. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996; 10: 1649-1655.
44. Van der Ende ME, Guillon C, Boers PH et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25: 11-18.
45. Tantillo C, Ding A, Jacobo-Molina A et al. Location of anti-AIDS drug binding site and resistance mutations in the three dimensional structure of HIV-1 reverse transcriptase. J Mol Biol 1994; 243: 369-387.
46. Descamps D, Damond F, Matheron S et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74: 197-201.
47. Rodes B, Toro C, Jimenez V et al. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. CID 2005; 41: e19-e21.
48. Damond F, Matheron S, Peytavin G et al. Selection of K65R mutation in HIV-2 infected patients receiving tenofovir-containing regimen. Antivir Ther 2004; 9: 635-636.
49. Van Vaerenbergh K, Van Laetham K, Albert J et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44: 2109-2017.
50. Ntemgwa ML, Toni T, Brenner BG et al. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother 2009; 53: 708-715.
51. Schmit JC, Van Laetham K, Ruiz L et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998; 12: 2007-2015.
52. Rodriguez-Rosado R, Briones C, Soriano V. Introduction of drug resistance testing in clinical practice. AIDS 1999; 13: 1007-1014.
53. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA. Natural polymorphisms in the HIV-2 protease can accelerate time to development of resistance to Protease Inhibitors (PIs). Antimicrob Agents Chemother 2007; 51: 604-610.
54. Cavaco-Silva J, Miranda AC, Cabanas J et al. for the Portuguese HIV-2 Study Group. Amino acid substitutions selected by therapy in HIV-2 protease and reverse transcriptase. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract 633].
55. Desbois D, Roquebert B, Peytavin G et al. for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1545-1548.
56. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71: 298-305.
57. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9: 57-65.
58. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57: 709-713.
59. Maguire M, Shortino D, Klein A et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type-1 infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46: 731-738.
60. Jallow S, Kaye S, Alabi A et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20: 1455-1458.
61. Mullins C, Eisen G, Popper S et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38: 1771-1779.
62. Bénard A, Damond F, Campa P et al. for the ANRS CO5 HIV-2 Cohort Study Group. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS 2009; 23: 1171-1173.
63. Rodes B, Toro C, Sheldon J et al. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20: 127-129.
64. Brandin E, Lindborg L, Gyllensten K et al. Pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2003; 19: 543-550.
65. Parkin N, Chappey C, Petropoulos C. Improving lopinavir genotype algorithm through phenotype correlations; novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17: 955-961.
66. Masse S, Lu X, Dekhtyar T et al. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother 2007; 51: 3075-3080.
67. Koh Y, Nakata H, Maeda K et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-3129.
68. Whitcomb J, Huang W, Fransen S et al. Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract 557].
69. Roquebert B, Damond F, Collin G et al. for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62: 914-920.
70. Damond F, Lariven S, Roquebert B et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22: 665-666.
71. Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antivir Res 2005; 68: 96-108.
72. Owen SM, Ellenberger D, Rayfield M et al. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol 1998; 72: 5425-5432.
73. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Available at (accessed 4 February 2010).
74. Jallow S, Alabi A, Sargee-Njie R et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol 2009; 47: 2200-2208.
75. Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23: 426-428.
76. Gilks CF, Crowley S, Ekpini R et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-510.
77. Benard A, Taieb A, Van Sighem A et al. for the ACHIEV2E study group. Immuno-virological response to triple NRTI and boosted PI in treatment-naïve HIV-2-infected patients. European AIDS Clinical Society Conference. Cologne, November 2009 [Abstract PS10/5].
78. Schutten M, Van Der Ende M, Osterhaus A et al. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. NEJM 2000; 23: 1758-1760.
79. De Ruiter A, Mercey D, Anderson J et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Medicine 2008; 9: 452-502.